Armistice Capital’s NanoViricides NNVC Stock Holding History

Armistice Capital’s Portfolio NNVC Stock Details NNVC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-1,368,000	Closed	-$1.55M	–	405
2025 Q4	$1.55M	Buy	+1,368,000	New	+$1.92M	0.02%	164

Other funds holding NNVC

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

MFS

Miller Financial Services Marshall, Michigan $124M AUM 17.62% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

Squarepoint New York $90.5B AUM 33.95% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Armistice Capital's NNVC Position: Q1 2026 in Review

Armistice Capital sold out of NanoViricides (NNVC) in Q1 2026, closing a stake of 1,368,000 shares — an estimated $1.55M sold.

Armistice Capital first reported a position in NNVC in Q4 2025 and held it in 1 quarter. The position peaked at $1.55M in Q4 2025. 48 funds tracked by Wall St. Rank hold NNVC as of Q1 2026.

Armistice Capital reported no remaining NanoViricides position as of Q1 2026 after selling out during the quarter.
Armistice Capital sold 1,368,000 NanoViricides shares in Q1 2026, an estimated $1.55M.
Armistice Capital first reported a position in NanoViricides in Q4 2025 and held it in 1 quarter.
Armistice Capital's NanoViricides position peaked at $1.55M in Q4 2025.
48 funds tracked by Wall St. Rank held NanoViricides as of Q1 2026.

Based on Armistice Capital's 13F filing for Q1 2026, filed 15 May 2026.